This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Kaneko, T. Articles by LePage, G. A. Search for Related Content PubMed PubMed Citation Articles by Kaneko, T. Articles by LePage, G. A.

Studies on ß-D-Xylofuranosyl-6-thioguanine in Mice¹

Life Science Research, Stanford Research Institute, Menlo Park, California 94025

9-ß-D-Xylofuranosyl-6-thioguanine (Xyl-TG) was tested against three murine ascites tumor lines, including one resistant to 6-thioguanine. It extended survivals of mice bearing Ca755, TA3, and Ehrlich TGRII tumors at a dose of 20 mg/kg only when combined with azaserine. A 100 mg/kg dose level of Xyl-TG alone appeared to give immunosuppressive effects in mice bearing Ehrlich TGRII cells, since survival was shorter than for controls. Limited inhibition of incorporation of purines and pyrimidines into microsomal and soluble RNA's were observed in cells treated with Xyl-TG. Mice excreted Xyl-TG rapidly in the urine, without any indication of the catabolism that occurs with natural purine nucleosides.

¹ This research was supported by USPHS Grant CA 10938 from the National Cancer Institute.

² Present address: University of Texas M. D. Anderson Hospital and Tumor Institute at Houston, Houston, Texas 77025.

Received 6/ 9/69. Accepted 8/ 6/69.